Nebuflow is a pioneering startup focused on revolutionizing respiratory drug delivery through advanced nebuliser technology. The company has developed a new generation of nebulisers that can deliver a broader range of drug formulations than current technologies. This includes the delivery of biologics, which are the next wave of inhaled drugs, and other high-value therapeutics like vaccines.

Nebuflow primarily serves pharmaceutical companies and healthcare providers who are looking to improve the efficiency and effectiveness of drug delivery to the lungs. The market it operates in is the respiratory drug delivery sector, which is a critical segment of the broader pharmaceutical and healthcare industry.

The business model of Nebuflow involves partnering with pharmaceutical companies to integrate its patented aerosol formation technology into their drug delivery systems. This technology uses surface acoustic waves (SAWs) generated on piezoelectric materials to create vibrations that lead to the efficient ejection of drug droplets. This allows for the effective delivery of drugs that are typically hard to nebulise.

Nebuflow generates revenue through a combination of licensing its technology, securing grants, and attracting equity investments. The company has already secured significant funding from notable investors such as Foresight Williams Technology, Science Creates Venture, Ascension, and SIS Venture.

The company is supported by an advisory board of experienced professionals, including Dr. Gary Pitcairn, an expert in inhaled drug delivery, and Dr. Helen Erwood, a veteran in regulatory affairs. This strong leadership team underscores Nebuflow's commitment to innovation and regulatory compliance.

Keywords: nebuliser technology, respiratory drug delivery, biologics, vaccines, pharmaceutical partnerships, aerosol formation, surface acoustic waves, healthcare innovation, drug delivery efficiency, equity investment.